More drug prices are likely to be announced over the course of January — historically the biggest month for drugmakers to raise prices.
The industry is also contending with inflation and supply chain constraints that have led to higher manufacturing costs. To date, Pfizer announced the most increases, with prices rising on 89 unique drug brands and an additional increase on 10 drug brands at its Hospira arm. A company spokesperson said there were several driving factors in increasing the list price of the two CAR-T cell therapies, including the rate of inflation, the value of the therapies, and the personalised nature of the CAR-T manufacturing process.
Wir haben diese Nachrichten zusammengefasst, damit Sie sie schnell lesen können. Wenn Sie sich für die Nachrichten interessieren, können Sie den vollständigen Text hier lesen. Weiterlesen:
Sue them.